FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081239366> ?p ?o ?g. }

• W3081239366 endingPage "1381" @default.
• W3081239366 startingPage "1371" @default.
• W3081239366 abstract "Introduction Carcinogenesis is driven by an array of complex genomic patterns; these patterns can render an individual resistant or sensitive to certain chemotherapy agents. The Personalized Oncogenomics (POG) project at BC Cancer has performed integrative genomic analysis of whole tumour genomes and transcriptomes for over 700 patients with advanced cancers, with an aim to predict therapeutic sensitivities. The aim of this study was to utilize the POG genomic data to evaluate a discrete set of biomarkers associated with chemo-sensitivity or-resistance in advanced stage breast and colorectal cancer POG patients. Methods This was a retrospective multi-centre analysis across all BC CANCER sites. All breast and colorectal cancer patients enrolled in the POG program between July 1, 2012 and November 30, 2016 were eligible for inclusion. Within the breast cancer population, those treated with capecitabine, paclitaxel, and everolimus were analyzed, and for the colorectal cancer patients, those treated with capecitabine, bevacizumab, irinotecan, and oxaliplatin were analyzed. The expression levels of the selected biomarkers of interest ( EPHB4, FIGF, CD133, DICER1, DPYD, TYMP, TYMS, TAP1, TOP1, CKDN1A, ERCC1, GSTP1, BRCA1, PTEN, ABCB1, TLE3, and TXNDC17) were reported as mRNA percentiles. Results For the breast cancer population, there were 32 patients in the capecitabine cohort, 15 in the everolimus cohort, and 12 in the paclitaxel cohort. For the colorectal cancer population, there were 29 patients in the bevacizumab cohort, 12 in the oxaliplatin cohort, 29 in the irinotecan cohort, and 6 in the capecitabine cohort. Of the biomarkers evaluated, the strongest associations were found between Bevacizumab-based therapy and DICER1 (P = 0.0445); and between capecitabine therapy and TYMP (P = 0.0553). Conclusions Among breast cancer patients, higher TYMP expression was associated with sensitivity to capecitabine. Among colorectal cancer patients, higher DICER1 expression was associated with sensitivity to bevacizumab-based therapy. This study supports further assessment of the potential predictive value of mRNA expression of these genomic biomarkers." @default.
• W3081239366 created "2020-09-01" @default.
• W3081239366 creator A5001476786 @default.
• W3081239366 creator A5001731680 @default.
• W3081239366 creator A5009916787 @default.
• W3081239366 creator A5026112445 @default.
• W3081239366 creator A5028570084 @default.
• W3081239366 creator A5046710365 @default.
• W3081239366 creator A5070061359 @default.
• W3081239366 creator A5079164469 @default.
• W3081239366 creator A5088331751 @default.
• W3081239366 creator A5089913686 @default.
• W3081239366 date "2020-08-26" @default.
• W3081239366 modified "2023-10-12" @default.
• W3081239366 title "Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer" @default.
• W3081239366 cites W1898161046 @default.
• W3081239366 cites W1965076070 @default.
• W3081239366 cites W1991563094 @default.
• W3081239366 cites W1996114369 @default.
• W3081239366 cites W2003633753 @default.
• W3081239366 cites W2005891421 @default.
• W3081239366 cites W2007812652 @default.
• W3081239366 cites W2018041181 @default.
• W3081239366 cites W2032754836 @default.
• W3081239366 cites W2037718375 @default.
• W3081239366 cites W2038454593 @default.
• W3081239366 cites W2044586762 @default.
• W3081239366 cites W2062117097 @default.
• W3081239366 cites W2077330022 @default.
• W3081239366 cites W2102433244 @default.
• W3081239366 cites W2136662615 @default.
• W3081239366 cites W2154431984 @default.
• W3081239366 cites W2156001194 @default.
• W3081239366 cites W2262414037 @default.
• W3081239366 cites W2268285310 @default.
• W3081239366 cites W2276692235 @default.
• W3081239366 cites W2284353757 @default.
• W3081239366 cites W2296708797 @default.
• W3081239366 cites W2341308894 @default.
• W3081239366 doi "https://doi.org/10.1177/1078155220951845" @default.
• W3081239366 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32847480" @default.
• W3081239366 hasPublicationYear "2020" @default.
• W3081239366 type Work @default.
• W3081239366 sameAs 3081239366 @default.
• W3081239366 citedByCount "2" @default.
• W3081239366 countsByYear W30812393662022 @default.
• W3081239366 crossrefType "journal-article" @default.
• W3081239366 hasAuthorship W3081239366A5001476786 @default.
• W3081239366 hasAuthorship W3081239366A5001731680 @default.
• W3081239366 hasAuthorship W3081239366A5009916787 @default.
• W3081239366 hasAuthorship W3081239366A5026112445 @default.
• W3081239366 hasAuthorship W3081239366A5028570084 @default.
• W3081239366 hasAuthorship W3081239366A5046710365 @default.
• W3081239366 hasAuthorship W3081239366A5070061359 @default.
• W3081239366 hasAuthorship W3081239366A5079164469 @default.
• W3081239366 hasAuthorship W3081239366A5088331751 @default.
• W3081239366 hasAuthorship W3081239366A5089913686 @default.
• W3081239366 hasConcept C121608353 @default.
• W3081239366 hasConcept C126322002 @default.
• W3081239366 hasConcept C143998085 @default.
• W3081239366 hasConcept C2776694085 @default.
• W3081239366 hasConcept C2777802072 @default.
• W3081239366 hasConcept C2777909004 @default.
• W3081239366 hasConcept C2780259306 @default.
• W3081239366 hasConcept C2780962732 @default.
• W3081239366 hasConcept C2908647359 @default.
• W3081239366 hasConcept C526805850 @default.
• W3081239366 hasConcept C530470458 @default.
• W3081239366 hasConcept C71924100 @default.
• W3081239366 hasConcept C72563966 @default.
• W3081239366 hasConcept C99454951 @default.
• W3081239366 hasConceptScore W3081239366C121608353 @default.
• W3081239366 hasConceptScore W3081239366C126322002 @default.
• W3081239366 hasConceptScore W3081239366C143998085 @default.
• W3081239366 hasConceptScore W3081239366C2776694085 @default.
• W3081239366 hasConceptScore W3081239366C2777802072 @default.
• W3081239366 hasConceptScore W3081239366C2777909004 @default.
• W3081239366 hasConceptScore W3081239366C2780259306 @default.
• W3081239366 hasConceptScore W3081239366C2780962732 @default.
• W3081239366 hasConceptScore W3081239366C2908647359 @default.
• W3081239366 hasConceptScore W3081239366C526805850 @default.
• W3081239366 hasConceptScore W3081239366C530470458 @default.
• W3081239366 hasConceptScore W3081239366C71924100 @default.
• W3081239366 hasConceptScore W3081239366C72563966 @default.
• W3081239366 hasConceptScore W3081239366C99454951 @default.
• W3081239366 hasIssue "6" @default.
• W3081239366 hasLocation W30812393661 @default.
• W3081239366 hasOpenAccess W3081239366 @default.
• W3081239366 hasPrimaryLocation W30812393661 @default.
• W3081239366 hasRelatedWork W1838719144 @default.
• W3081239366 hasRelatedWork W1963586822 @default.
• W3081239366 hasRelatedWork W1966121666 @default.
• W3081239366 hasRelatedWork W1997133872 @default.
• W3081239366 hasRelatedWork W2010928484 @default.
• W3081239366 hasRelatedWork W2020685114 @default.
• W3081239366 hasRelatedWork W2035875009 @default.
• W3081239366 hasRelatedWork W2037813108 @default.
• W3081239366 hasRelatedWork W2050348440 @default.

• next